Speakers

Expand/Collapse

Felix Faupel
Chief Commerical Officer
BacThera

Day Two

Thursday, July 1 2021

9:30 am | Solving LBP Manufacturing Challenges: Introducing BacThera & Industry Changing Downstream Technologies

Jiri Snaidr
Founder & CEO
vermicon AG

Day Two

Thursday, July 1 2021

10:45 am | Deeper Understanding Of the Microbiome Composition and Interactions Using the Alternative Microbiological Methods FISH and Flow Cytometry

Nicolas Delahaye
Director - Technology Project Leader
GSK

Track A - Day 2 PM

2:15 pm | Modulation of the Gut Microbiota to Improve Vaccine- Induced Immunity

Christophe Carite
Director, CMC & Development
4D Pharma

Track B - Day 2 PM

2:30 pm | Effectively Scaling Up Microbiome Manufacturing

Christopher Missling
CEO
Anavex Corp

Track C - Day 2 AM

1:00 pm | Exploring Gut Microbiota as a Source of Potential Biomarkers

Mark Bamforth
President & CEO
Arranta Bio

Mark Bamforth founded a new CDMO, Arranta Bio, in May 2019. Previously, Mark founded Brammer Bio in 2015, a best-in-class viral vector contract development and manufacturing organization (CDMO) supporting cell and gene therapies. Brammer’s team grew from 110 in 2016 with the addition of 100 from the acquisition of two Biogen commercial facilities, to over 600 at the time of its acquisition by Thermo Fisher Scientific in April 2019. In 2010, Mark founded a biologics CDMO, Gallus BioPharmaceuticals, and acquired a world-class facility and team of 160 from J&J with a commercial supply agreement. Gallus tripled through organic growth and merging with Laureate Biopharma. Gallus was sold to DPx Holdings B.V. in Sept. 2014. Mark previously spent 22 years in the UK and USA running a global manufacturing operation and a pharmaceutical CMO business for Genzyme and served as a corporate officer for 9 years. He began his career as a petroleum engineer exploring for North Sea oil with Britoil, then as a chemical engineer in the whisky industry with Whitbread. Mark serves on the boards of Avid Bioservices, MassBio, Wentworth Institute of Technology, and Entrepreneurial Scotland. He has a BS in Chemical Engineering from Strathclyde University and an MBA from Henley Management College.

Day One

Wednesday, June 30 2021

11:15 am | Meeting the Maturing Supply Needs of the Microbiome Sector

Taylor Cohen
Principal Scientist
AstraZeneca

Track A - Day 1 AM

12:40 pm | Examining the Role of the Microbiome in Metabolic Disease

David Donabedian
CEO
Axial Therapeutics

Dr. Donabedian is an accomplished business development and strategy executive with extensive leadership experience. Dr. Donabedian has a track record of building companies, most recently as a Venture Partner at Longwood Fund. Prior to joining Longwood, Dr. Donabedian has held various leadership roles at biopharmaceutical companies including AbbVie and GSK. At AbbVie, Dr. Donabedian served as Vice President & Global Head of Ventures and Early Stage Collaborations where he led a global team that completed significant transactions across multiple therapeutic areas and stages of development. Prior to AbbVie, Dr. Donabedian served as Vice President Global New Deal Strategy and Development at GlaxoSmithKline, and Senior Manager at Accenture’s Strategic Services Consulting Group. He holds a BA in Chemistry from St. Anselm College, a Ph.D. in Polymer Chemistry from the University of Massachusetts Lowell, and an MBA from the University of North Carolina. He currently serves on the Board of Alcyone Life Sciences, a privately held CNS company which he co-founded.

Track B - Day 2 PM

3:45 pm | Disruptive Approaches to Treat CNS Disease Via the Gut-Brain Axis

Travis Whitfill
Co-Founder
Azitra

Day One

Wednesday, June 30 2021

5:30 pm | Closing Remarks – Day One

9:00 am | Industry Leaders Panel Discussion

8:55 am | Chair’s Opening Remarks

Jean-Marc Billod
CTO
Bio-Me

Track C - Day 2 PM

2:45 pm | Exploring Microbiome Diagnostics

Morten Isaksen
CEO
Bio-Me

Track C - Day 2 PM

2:25 pm | Microbiome Analytics in a Clinical Setting

Jonathan Solomon
CEO
BiomX

Track A - Day 2 AM

12:30 pm | Phage Therapies to Eradicate Pathogenic Bacteria in Chronic Indications

Assaf Oron
CBO
BiomX

Assaf Oron has served as chief business officer since January 2017. Prior to this position, he served for over a decade at Evogene (NYSE:EVGN), an agriculture biotechnology company which utilizes a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. At Evogene, he worked in various roles such as executive vice president of corporate development and executive vice president of strategy and business development. From 2004 to 2006, Mr. Oron served as CEO of ChondroSite Ltd., a biotechnology company that develops engineered tissue products in the field of orthopedics. From 1999 to 2003, Mr. Oron was a senior project manager and strategic consultant at POC Ltd., a leading Israeli management consulting company. Mr. Oron holds an M.Sc. in Biology (bioinformatics) and a B.Sc. in Chemistry and Economics, both from Tel Aviv University.

Track C - Day 1 AM

12:10 pm | Xmarker – A Novel Platform to Discover Microbiome Based Biomarkers

Track C - Day 1 AM 2

2:30 pm | Panel Discussion – What Are We Looking for in a Microbiome Biomarker?

Adrien Nivolez
CEO
Biose Industrie

Track B - Day 2 AM

1:00 pm | Building a Strategic Partnership to Effectively Scale & Manufacture Microbiome Based Therapeutics

Yvonne Nyavor
Principal Scientist, Microbiome
Boston Analytical

Day One

Wednesday, June 30 2021

10:15 am | Microbiome Endgame: Preparing Microbiome Products for Regulatory Requirements Through cGMP Program Design

Brian Klein
CEO
BrickBuilt Therapeutics

Nancy Caralla
Founding President & Executive Director
C.diff Foundation

Day Two

Thursday, July 1 2021

4:45 pm | Bringing it Back to the Patient - The Importance of Microbiome Therapeutics for the Treatment of C.difficile infection

Dan Knights
CEO
CoreBiome

Dan Knights is a computer scientist, computational biologist, and globally recognized expert in microbiome informatics who has developed some of the leading methods for analyzing microbiome data. He directs informatics & software development at CoreBiome, and was educated at Middlebury, University of Colorado, and Harvard Medical School.

Manoj Dadlani
CEO
CosmosID

Gerard Honig
Associate Director, Research Innovation
Crohn’s & Colitis Foundation

Track C - Day 1 AM 2

2:30 pm | Panel Discussion – What Are We Looking for in a Microbiome Biomarker?

Jean De Gunzburg
CSO
Da Volterra

Track B - Day 1 AM

12:40 pm | Protecting and Preserving the Intestinal Microbiota From Antibiotic-Induced Dysbiosis With dav132, a Novel Colon-Targeted Adsorbent: An Effective and Safe Solution for Cancer Patients

Chengwei Luo
CEO
DeepBiome Therapeutics

Track A - Day 1 PM

5:00 pm | Inventing Medicine by Accessing the Microbiome Dark Matter

Denise Barbut
Co-Chairman, Co- Founder & CMO
Enterin

Track B - Day 2 PM

4:15 pm | Targeting the Enteric Neuron to Treat Parkinson’s Disease

Paul Carlson
Principal Investigator
FDA

Day Two

Thursday, July 1 2021

9:00 am | Regulatory Considerations for Microbiome-based Therapeutics

Emily Drabant Conley
CEO
Federation Bio

Day Two

Thursday, July 1 2021

10:15 am | Panel Discussion: How Has Late Stage Clinical Success Impacted Investment Within the Microbiome Space?

Track A - Day 1 AM

12:10 pm | Health Through Diversity: Designing Microbial Consortia for Lasting Benefit

Natalie Ma
CBO
Felix Biotech

Track A - Day 2 AM

1:00 pm | Phages as Microbiome-Editing Tools and Therapeutics

Mark Smith
CEO
Finch Therapeutics

Day One

Wednesday, June 30 2021

9:00 am | Industry Leaders Panel Discussion

Sonia Timberlake
VP Research
Finch Therapeutics

Dr. Sonia Timberlake is the VP of Research at Finch Therapeutics, a microbiome therapeutics company. Sonia is an expert at designing NGS-based algorithms for applications in microbial genomics, immunogenomics, and evolution. Prior to joining Finch, she built and managed AbVitro's computational algorithms and infrastructure, supporting high throughput single-cell immune phenotyping and repertoire sequencing technology. This technology platform was acquired by Juno Therapeutics, where Sonia led a multidisciplinary team to harness native adaptive immune responses for developing engineered cell therapies in oncology. Sonia graduated from Caltech with a B.Sc in Molecular Biology and received her Ph.D. in Biological Engineering from MIT.

Track B - Day 1 AM 2

2:30 pm | A Human-First Discovery Approach: Leveraging Clinical Data to Identify Microbial Communities Driving Positive Clinical Outcomes

Andrea Nuzzo
Computational Biologist
GSK

Track A - Day 1 PM

4:30 pm | Expanding the Drug Discovery Space With Predicted Metabolite-Target Interactions

Kate Jefferey
Assistant Professor of Medicine
Harvard Medical School

PRE-CONFERENCE IMMUNE-DISEASE FOCUS DAY

11:00 am | Immunomodulation by the Human Enteric Virome

Timothy Wannier
Postdoctoral Fellow
Harvard Medical School

Track A - Day 2 PM

4:15 pm | Toward Universal Functional Genomics: Enabling Efficient Recombineering in Diverse Bacteria

Sean Gibbons
Assistant Professor
Institute Systems Biology

Track C - Day 2 PM

4:15 pm | Towards Rational Engineering of Gut Microbiome Metabolic Outputs

Julia Drewes
Assistant Professor of Medicine
John Hopkins Medical Center

PRE-CONFERENCE IMMUNE-DISEASE FOCUS DAY

1:30 pm | Mechanisms of Colonic Biofilm-Associated Tumorigenesis

9:00 am | Panel Discussion – What do we need to know about the interaction between the microbiome and the immune system?

Fyza Shaikh
Instructor
John Hopkins Medical Center

PRE-CONFERENCE IMMUNE-DISEASE FOCUS DAY

2:30 pm | Single Pipeline Re-Analysis Revises Microbiome Associations With Anti-Tumor Response to Checkpoint Inhibitors

Daniel Meninchella
CEO
Kaleido Bioscience

Day One

Wednesday, June 30 2021

9:00 am | Industry Leaders Panel Discussion

Johan van Hylckama Vlieg
CSO
Kaleido Biosciences

Dr. van Hylckama Vlieg has served as Kaleido's Chief Scientific Officer since July 2019. Dr. van Hylckama Vlieg has 25 years of experience leading teams and R&D programs in gut microbiology, probiotics and live biotherapeutics, and industrial biotechnology in industry and academia. Most recently, he served as Vice President for Microbiome and Human Health Innovation at Chr. Hansen in Denmark, responsible for new strain development for probiotic and therapeutic application, spanning discovery to clinical development and novel technology platforms. Previously, Dr. van Hylckama Vlieg worked at Danone Research and in several roles at NIZO Food Research. He completed his Ph.D. and post-doc in biochemistry at the University of Groningen in the Netherlands.

Track A - Day 1 PM

4:00 pm | Synthetic Glycans to Optimize Microbiome Composition & Function for Therapeutic Outcomes

Stacy Burns-Guydish
President
List Laboratories

Track B - Day 1 AM

12:00 pm | Overcoming Obstacles in the Development of Live Biotherapeutic Products

Tuval Ben-Yehezkel
CEO
Loop Genomics

Stacy Kahn
Attending Gastroenterologis
Massachusetts General Hospital

Dr. Stacy Kahn completed her undergraduate degree in history at Washington University in St. Louis, and her post-baccalaureate premedical training at Bryn Mawr College in Pennsylvania. She attended New York University School of Medicine and then went on to complete her pediatric residency and pediatric gastroenterology fellowship at the University of Chicago. While at the University of Chicago, she also completed an ethics fellowship at the Maclean Center for Clinical Medical Ethics. Clinically, Dr. Kahn’s interests have focused on the care of children with IBD, in particular she is interested in the care and management of teens and young adults with Crohn’s and colitis. While on the faculty at the University of Chicago, she founded and was the Director for the Transitional IBD Clinic. Dr. Kahn's other primary clinical focus is recurrent and refractory Clostridium difficile infection. She is a national expert and leader in the field of fecal microbiota transplantation (FMT) and performed the first colonoscopic FMT in a child. Dr. Kahn's research interests include FMT for Clostridium difficile, FMT for inflammatory bowel disease, transition of care and self-management in IBD and research ethics. She is the director of the FMT research program at Boston Children’s Hospital and has led the development of the first national pediatric FMT registry.

Track B - Day 1 PM

4:10 pm | Designing & Executing Microbiome-Therapeutic Clinical Trials

Gokul Swaminathan
Associate Principal Scientist, Investigational Biology
Merck Exploratory Science

Track A - Day 1 AM 2

3:00 pm | Pre-Clinical Animal Models to Understand the Influence of the Microbiome on the Host-Immune System

Xue Liang
Microbiome Scientist
Merck Exploratory Science Center

Track C - Day 2 AM

12:30 pm | Xenobiotic Metabolism: The Role of the Gut Microbiome

Sandrine Miller Montgomery
CEO
Micronoma

Track C - Day 2 PM

3:15 pm | Tissue & Circulating Microbiomes – The New Frontier

Bharat Dixit
VP, Biopharmaceutical Development & Manufacturing
Morningside BioPharma Advisory

Track B - Day 2 PM

2:30 pm | Effectively Scaling Up Microbiome Manufacturing

Louis Cohen
Assistant Professor
Icahn School of Medicine, Mount Sinai

PRE-CONFERENCE IMMUNE-DISEASE FOCUS DAY

10:30 am | Moving Towards Live Biotherapeutics for Inflammatory Bowel Disease

9:00 am | Panel Discussion – What do we need to know about the interaction between the microbiome and the immune system?

Mark Fitzgerald
Partner
Nixon Peabody

Track B - Day 2 PM

3:15 pm | Achieving IP on a Microbiome Therapeutics

Blake Wise
CEO
Novome Biotechnologies

Track A - Day 2 PM

3:15 pm | Engineering Colonizing Microbes for Therapeutic Function

Christine Spencer
Senior Research Scientist
Parker Institute

PRE-CONFERENCE IMMUNE-DISEASE FOCUS DAY

2:00 pm | Going Bold on Cancer Immunotherapy and the Gut Microbiome

9:00 am | Panel Discussion – What do we need to know about the interaction between the microbiome and the immune system?

Stephanie Culler
Co-Founder & CEO
Persephone Biosciences

Day One

Wednesday, June 30 2021

9:00 am | Industry Leaders Panel Discussion

Maireadh Pedersen
CEO
Quay Pharma

Track B - Day 1 AM 2

2:00 pm | Development of Microbiome Drug Products

Ken Blount
CSO
Rebiotix

Ken Blount, PhD, is a seasoned director of collaborative research programs in biotech, pharma, clinical, and academic research settings, and his scientific expertise includes antibiotics discovery and development, fecal microbiome analysis, translational medical oncology, and RNA-targeting therapeutics. Prior to joining Rebiotix, Dr. Blount coordinated translational urologic oncology research for the Yale Cancer Center. Previously, he was a cofounder and the Director of Biology at BioRelix, a venture-backed Connecticut biotech that developed new antibiotics to target structured bacterial messenger RNAs. At BioRelix, Dr. Blount led a combined force of internal scientists and external resources that delivered development candidates for treating Clostridium difficile infections. Dr. Blount received his undergraduate degree in biochemistry from the University of Arkansas and earned a PhD in biochemistry from the University of Colorado Boulder, after which he completed an NIH post-doctoral fellowship at the University of California San Diego.

Day One

Wednesday, June 30 2021

9:00 am | Industry Leaders Panel Discussion

Paul Plumb
Director, Clinical Development
Rebiotix

Track B - Day 1 AM

12:10 pm | Forging a New Frontier – Driving Clinical Development of RBX2660, a Novel Live Biotherapeutic

Jeanette Mucha
CEO
SciBac

Track A - Day 1 AM 2

2:30 pm | Live Biotherapeutics to Treat and Prevent Chronic Lung Infections

Scott Plevy
CSO
Senda Biosciences

Day Two

Thursday, July 1 2021

5:00 pm | Closing Remarks

10:15 am | Panel Discussion: How Has Late Stage Clinical Success Impacted Investment Within the Microbiome Space?

8:55 am | Chair’s Opening Remarks

Track C - Day 2 PM

3:45 pm | InterSystems Biology: The Next Frontier in Drug Discovery

Eric Shaff
CEO
Seres Therapeutics

Eric Shaff is the President and Chief Executive Officer of Seres. Mr. Shaff was previously the Executive Vice President, Chief Operating and Financial Officer of Seres. He has more than 15 years of experience working in leadership roles in biotechnology finance, corporate development, and capital markets. Prior to joining Seres, he was Vice President, Corporate Finance, at Momenta Pharmaceuticals, where he helped manage Momenta’s accounting, finance, planning, and procurement functions, as well as contributing to Momenta’s investor relations efforts. Prior to joining Momenta, Mr. Shaff was Vice President, Finance, of Genzyme’s Rare Genetic Disease Division, responsible for a global portfolio of products. Mr. Shaff held several positions at Genzyme in business unit finance, corporate finance, and corporate development. Prior to Genzyme, Mr. Shaff worked in corporate finance at Pfizer and worked in investment banking for Broadview International (now Jefferies LLC). Mr. Shaff earned his B.A. from the University of Pennsylvania in political science and economics and his M.B.A. with a concentration in finance from the Johnson Graduate School of Management at Cornell University.

Day One

Wednesday, June 30 2021

9:00 am | Industry Leaders Panel Discussion

Matthew Henn
Executive VP & CSO
Seres Therapeutics

Day One

Wednesday, June 30 2021

10:45 am | Developing Bacterial Consortia Therapeutics for Infectious and Inflammatory Disease Targets

David Ege
CTO
Seres Therapeutics

Track B - Day 2 PM

2:30 pm | Effectively Scaling Up Microbiome Manufacturing

Chris Ford
Senior Director, Computational Microbiome Scientist
Seres Therapeutics

Track C - Day 1 PM

4:00 pm | Biomarkers to Evaluate Microbiome Therapeutic Drug Pharmacokinetics & Pharmacodynamics

Denise Kelly
Investment Advisor
Seventure Partners

Day Two

Thursday, July 1 2021

10:15 am | Panel Discussion: How Has Late Stage Clinical Success Impacted Investment Within the Microbiome Space?

Nikole Kimes
CEO
Siolta Therapeutics

Track C - Day 1 AM 2

2:30 pm | Panel Discussion – What Are We Looking for in a Microbiome Biomarker?

Ricardo Valladares
CSO
Siolta Therapeutics

Track C - Day 2 PM

2:45 pm | Exploring Microbiome Diagnostics

Mark Charbonneau
Head, Quantitative Biology
Synlogic

Track A - Day 2 PM

3:45 pm | Development of a Synthetic Biotic for the Treatment of Enteric Hyperoxaluria

Julie Schwedock
Associate Director, Microbial Development
Takeda

Track B - Day 2 PM

2:30 pm | Effectively Scaling Up Microbiome Manufacturing

Joseph Maxwell
Associate Director, Translational Medicine
Takeda

Track C - Day 1 PM

4:30 pm | Biomarker Assay Development Considerations for Microbiome Therapies

Gregory Lambert
CEO and VP R&D
TargEDys

A Pharmacist, with a PhD in pharmaceutical technology, Gregory’s career has been split between Biotech and Pharma as Chief Scientific Officer and Chief Executive Officer in companies such as Novagali Pharma, Septodont and currently TargEDys. Gregory has led the development of several products from the laboratory to the market. In 2014, Gregory joined the scientific founders of TargEDys as CEO. Having completed preclinical development and produced industrial batches, TargEDys now concentrates on human clinical trials and commercial launch activities.

Track A - Day 2 PM

2:45 pm | A New Microbiome-Host Symbiosis, Lactobacillus Plantarum Wjl, a Precibiomic™ Strain Promoting Growth by Enhancing Host Capacity for Protein Degradation

R Balfour Sartor
Professor, Division of Gastroenterology & Hepatology
UNC Multidisciplinary IBD Center

PRE-CONFERENCE IMMUNE-DISEASE FOCUS DAY

10:00 am | Optimizing Pre-Clinical Models of Intestinal Inflammation to Better Translate Results of Microbiota Manipulation to Clinical Trials

Diwakar Davar
Assistant Professor, Melanome & Phase I Therapy
UPMC, Hillman Cancer Center

PRE-CONFERENCE IMMUNE-DISEASE FOCUS DAY

1:00 pm | Overcoming Resistance to Anti-PD-1 Therapy Through Microbiome Modulation

Benjamin Lelouvier
CSO
Vaiomer

Track C - Day 1 AM

12:00 pm | The Blood Microbiome: New Source of Biomarkers for Infectious & Cardiometabolic Diseases

Peter McCaffrey
CRO
VastBiome

Track C - Day 1 AM

12:40 pm | The Strategic Role of Microbiome Biomarkers in Diagnostics & Therapeutics

Bernat Olle
CEO
Vedanta Biosciences

Dr. Olle is a co-founder and Chief Executive Officer of Vedanta Biosciences. He has been a member of the founding teams of several companies of the PureTech portfolio and served as a member of the Board of Directors of Vedanta Biosciences and Follica Biosciences. In 2013 Dr. Olle was named "Innovator of the Year" in MIT Technology Review Spain's "Innovators under 35" awards. He completed his doctoral work at the Chemical Engineering Department at MIT, where he developed a novel method for large-scale bacterial culture. During his graduate work, Dr. Olle was awarded the "la Caixa" fellowship. Dr. Olle received his B.S. in Chemical Engineering from Universitat Rovira i Virgili, in the Republic of Catalonia, his M.S. and PhD. in Chemical Engineering Practice from MIT, and his M.B.A. from the MIT Sloan School of Management. He has published his work in journals including Nature and Nature Biotechnology.

Day One

Wednesday, June 30 2021

9:00 am | Industry Leaders Panel Discussion

Amanda Prince
Scientist II, Immunology
Vedanta Bioscience

PRE-CONFERENCE IMMUNE-DISEASE FOCUS DAY

3:00 pm | Chairperson’s Closing Remarks

8:55 am | Chairperson’s Opening Remarks